Research output: Contribution to journal › Article › peer-review
Antitumor efficacy of multi-target in situ vaccinations with CpG oligodeoxynucleotides, anti-OX40, anti-PD1 antibodies, and aptamers. / Proskurina, Anastasia S.; Рузанова, Вера Сергеевна; Риттер, Генрих Сергеевич et al.
In: Journal of Biomedical Research, Vol. 37, No. 3, 2023, p. 194-212.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Antitumor efficacy of multi-target in situ vaccinations with CpG oligodeoxynucleotides, anti-OX40, anti-PD1 antibodies, and aptamers
AU - Proskurina, Anastasia S.
AU - Рузанова, Вера Сергеевна
AU - Риттер, Генрих Сергеевич
AU - Ефремов, Ярослав Рейнгольдович
AU - Mustafin, Zakhar Sergeevich
AU - Лашин, Сергей Александрович
AU - Буракова, Екатерина Анатольевна
AU - Фокина, Алеся Анатольевна
AU - Zatsepin, Timofei S.
AU - Стеценко, Дмитрий Александрович
AU - Леплина, Ольга Юрьевна
AU - Останин, Александр Анатольевич
AU - Черных, Елена Рэмовна
AU - Bogachev, Sergey S.
N1 - Fundings: The work was supported by the Russian Ministry of Science and High Education via the Institute of Cytology and Genetics (State Budget Project No. FWNR-2022-0016) and Russian Foundation for Basic Research (Grant No. 18-29-09045).
PY - 2023
Y1 - 2023
N2 - To overcome immune tolerance to cancer, the immune system needs to be exposed to a multi-target action intervention. Here, we investigated the activating effect of CpG oligodeoxynucleotides, mesyl phosphoramidate CpG oligodeoxynucleotides, anti-OX40 antibodies, and OX40 RNA aptamers on major populations of immunocompetent cells ex vivo. Comparative analysis of the antitumor effects of in situ vaccination with CpG oligodeoxynucleotides and anti-OX40 antibodies, as well as several other combinations such as mesyl phosphoramidate CpG oligodeoxynucleotides and OX40 RNA aptamers, were conducted. Antibodies against programmed death 1 (PD1) checkpoint inhibitors or corresponding PD1 DNA aptamers were also added to vaccination regimens for analytical purposes. Four scenarios were considered: a weakly immunogenic Krebs-2 carcinoma grafted in CBA mice; a moderately immunogenic Lewis carcinoma grafted in C57Black mice; and an immunogenic A20 B cell lymphoma or an Erlich carcinoma, grafted in BALB/c mice. Adding anti-PD1 antibodies (CpG+αOX40+αPD1) to in situ vaccinations boosts the antitumor effect. When used instead of antibodies, aptamers also possess antitumor activity, although this effect was less pronounced. The strongest effect across all the tumors was observed in highly immunogenic A20 B cell lymphoma and Erlich carcinoma.
AB - To overcome immune tolerance to cancer, the immune system needs to be exposed to a multi-target action intervention. Here, we investigated the activating effect of CpG oligodeoxynucleotides, mesyl phosphoramidate CpG oligodeoxynucleotides, anti-OX40 antibodies, and OX40 RNA aptamers on major populations of immunocompetent cells ex vivo. Comparative analysis of the antitumor effects of in situ vaccination with CpG oligodeoxynucleotides and anti-OX40 antibodies, as well as several other combinations such as mesyl phosphoramidate CpG oligodeoxynucleotides and OX40 RNA aptamers, were conducted. Antibodies against programmed death 1 (PD1) checkpoint inhibitors or corresponding PD1 DNA aptamers were also added to vaccination regimens for analytical purposes. Four scenarios were considered: a weakly immunogenic Krebs-2 carcinoma grafted in CBA mice; a moderately immunogenic Lewis carcinoma grafted in C57Black mice; and an immunogenic A20 B cell lymphoma or an Erlich carcinoma, grafted in BALB/c mice. Adding anti-PD1 antibodies (CpG+αOX40+αPD1) to in situ vaccinations boosts the antitumor effect. When used instead of antibodies, aptamers also possess antitumor activity, although this effect was less pronounced. The strongest effect across all the tumors was observed in highly immunogenic A20 B cell lymphoma and Erlich carcinoma.
KW - immunogenicity
KW - Krebs-2 carcinoma
KW - Lewis carcinoma
KW - Erlich carcinoma
KW - A20 B cell lymphoma
KW - mesyl phosphoramidate
UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85167899121&origin=inward&txGid=fda2c4d84f501b2e29f081bf42056e80
UR - https://www.mendeley.com/catalogue/2cbe445d-45f5-3964-b6d7-14c9ad824468/
U2 - 10.7555/JBR.36.20220052
DO - 10.7555/JBR.36.20220052
M3 - Article
C2 - 37161885
VL - 37
SP - 194
EP - 212
JO - Journal of Biomedical Research
JF - Journal of Biomedical Research
SN - 1674-8301
IS - 3
ER -
ID: 43869033